Harvard prof David Sinclair backs anti-aging upstart Life Bio, which just raised $50M for research
You can add Life Biosciences to the list of biotech startups looking to make a name for themselves in the burgeoning field of anti-aging drug research.
The Boston-based biotech — which has close ties to David Sinclair, a Harvard geneticist who’s been involved in a variety of startups — says today that it’s lined up $50 million in B round cash. There’s no word on who exactly is investing in the company, but there’s no shortage of ambition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.